Stay updated on Disitamab Vedotin & Pembrolizumab in HER2+ Urothelial Cancer Clinical Trial

Sign up to get notified when there's something new on the Disitamab Vedotin & Pembrolizumab in HER2+ Urothelial Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Disitamab Vedotin & Pembrolizumab in HER2+ Urothelial Cancer Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    Page revision updated from v3.0.1 to v3.0.2; the 'Back to Top' element has been removed.
    Difference
    0.5%
    Check dated 2025-09-14T00:53:17.000Z thumbnail image
  2. Check
    12 days ago
    Change Detected
    Summary
    The web page has been updated to reflect a new revision version (v3.0.1) and includes a new date (2025-09-05) while removing the previous revision date (2025-08-26).
    Difference
    1%
    Check dated 2025-09-06T21:28:09.000Z thumbnail image
  3. Check
    19 days ago
    Change Detected
    Summary
    The web page has been updated to include a new facility name and location, along with a significant number of study status updates and dates, while some location-related terms have been removed.
    Difference
    76%
    Check dated 2025-08-30T15:57:29.000Z thumbnail image
  4. Check
    26 days ago
    No Change Detected
  5. Check
    33 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.11 to version 2.16.12.
    Difference
    0.3%
    Check dated 2025-08-16T12:54:30.000Z thumbnail image
  6. Check
    40 days ago
    Change Detected
    Summary
    The web page has been updated to a new version, v2.16.11, with the previous version, v2.16.10, being removed. Additionally, a date of August 7, 2025, has been added.
    Difference
    0.6%
    Check dated 2025-08-09T08:08:30.000Z thumbnail image
  7. Check
    48 days ago
    Change Detected
    Summary
    The web page has been updated to version 2.16.10, and a previous service alert regarding planned maintenance has been removed.
    Difference
    4%
    Check dated 2025-08-02T04:15:10.000Z thumbnail image

Stay in the know with updates to Disitamab Vedotin & Pembrolizumab in HER2+ Urothelial Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Disitamab Vedotin & Pembrolizumab in HER2+ Urothelial Cancer Clinical Trial page.